Once considered conceptual, cell and gene therapy has become a therapeutic reality for patients. Advances in cell and gene therapy led by innovative research and product development are enabling physicians to potentially reverse the debilitating trajectory of diseases, including rare and autoimmune diseases. The launch of (CAR) T-cell therapies such as Kymriah and Yescarta in